ReviewNature reviews. Cardiology2026
Soft robotic devices for cardiovascular medicine.
Review in Nature reviews. Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional, rigid simulators and therapeutic devices for cardiovascular disease have several fundamental limitations, such as poor biomimetic fidelity, substantial surgical invasiveness and mismatch at the tissue-device interface. Soft robotic devices, with tissue-like materials, structures and functions, are emerging as promising alternatives. In this Review, by matching clinical demands to technological breakthroughs, we identify three emerging complementary frontiers in which soft robotic devices are redefining cardiovascular medicine - soft robotic simulators, such as in vitro ventricular simulators and in vivo assistive simulators; soft robotic interventional instruments, such as percutaneous instruments, endovascular continuum instruments and untethered mini-scale robots; and soft robotic implants for vascular disease, arrhythmia and heart failure. We describe the unique advantages of soft robotic devices as well as their applicable scope and technical implementation. Finally, we highlight promising technological opportunities for next-generation soft cardiac devices, evaluate the clinical maturity of existing devices and propose a translational roadmap for the coming decade. With this Review, we aim to foster further integration of soft robotics into cardiovascular medicine by identifying device solutions with translational potential to address unmet clinical needs.
Identifiers
41998321What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.